Health Observance

National Influenza Vaccination Week

John Arnst
December 02, 2019

The year may be winding down, but flu season is still heating up. If you’ve been slacking on getting your annual shot, it’s not too late — in fact, the Centers for Disease Control and Prevention designated the first week of December as National Influenza Vaccination Week. While the flu vaccine remains the best line of defense against the fever, fatigue and range of respiratory symptoms of a genuine influenza infection, ASBMB members have been investigating how influenza viruses interact with our cells and uncovering leads for new antivirals and improved vaccines.

Why glycosylation matters in building a better flu vaccine

If influenza viruses were DNA-based, we may well have developed a universal vaccine decades ago. But, as retroviruses, they have a tendency to rack up errors every time they replicate, gradually changing the makeup of their hemagglutinin and neuraminidase proteins and slipping ever beyond the protective yoke of each season’s vaccine. While efforts to develop a universal flu vaccine are under way at labs around the world, flu vaccine design processes currently don’t account for the glycosylation that influenza A viruses, the primary cause of human influenza illnesses, use to evade host antibodies. Deborah Chang and Joseph Zaia at Boston University recently made the case in the journal Molecular & Cellular Proteomics that developing methods to determine site-specific glycosylation of glycoproteins in influenza A viruses could enhance the efficacy of future flu vaccines.

Forever in search of new antivirals

Developing new antivirals can feel like an exercise in futility — just over a year after the drug Xofluza was approved for distribution in the United States, scientists at the University of Wisconsin–Madison found that influenza viruses in a quarter of patients who took the drug developed resistance to it. While few drugs make it all the way through the development pipeline, biochemists are regularly discovering compounds that can take advantage of novel mechanisms to inhibit viral replication.

Histone deacetylases play a role in preventing influenza replication

Like almost all viruses, influenza A viruses hijack host machinery to replicate. In response to evidence that an optimal acetylation environment in host cells is favorable to this process, researchers at the University of Otago in New Zealand investigated the effects of histone deacetylases, which negatively regulate acetylation, against IAVs.

Influenza viruses love lipids

After influenza has hijacked a host cell’s machinery to crank out its RNA and proteins, it needs to get them wrapped in a protective lipid envelope so that new virions can venture forth and infect more host cells. Researchers at the University of Singapore recently used a mass spectrometry-based lipidomics approach to investigate how IAVs interact with the host cells’ lipid metabolism during different stages of infection. They found that function of membrane-bound peroxisomes to be a common metabolic denominator and a potential key determinant for influenza virus replication.

Gut microbes, glycosphingolipids and influenza

Invariant natural killer T cells are versatile — they thwart tumors, attack pathogenic bacteria viruses and play a role in autoimmune diseases — and the glycosphingolipid α-galactosylceramide, produced by Bacteroides in the human gut, is key to their activation. Researchers at the University of Marburg and German Cancer Research Center recently found that conditions including colitis, consumption of a Western diet and infection by influenza A virus tend to decrease levels of αGalCer. This suggests that modulating gut microbial-derived immunogenic lipids including αGalCerML may impact immunity.

Hosts and their viruses: a thematic series of review articles

Hot off the heels of the swine flu epidemic — an H5N1 strain from the antigenic shift that happened when two starkly different influenza strains infected the same pig population — Charles Samuel helped organize a JBC minireview series with the aim of understanding the structural basis for interactions between influenza viruses and host cells. Read the series.

John Arnst

John Arnst is a science writer for ASBMB Today.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.

Multiomics meets antimalarials
Journal News

Multiomics meets antimalarials

March 31, 2020

Researchers in Australia use an innovative multiomics approach to analyze a new drug against malaria parasites.

From the journals: JLR
Journal News

From the journals: JLR

March 31, 2020

Topics include the role of HDL and Smo in inhibiting beta-cell apoptosis, lipid asymmetry in a plasma membrane and apolipoproteins and dementia risk.

Researchers retool genomics labs to provide COVID-19 testing
News

Researchers retool genomics labs to provide COVID-19 testing

March 30, 2020

The pipetting robots are already in place, but that doesn’t make it easy. Here's how academic laboratories are quickly pivoting to provide testing for the coronavirus.

Research on a budget
Essay

Research on a budget

March 30, 2020

As a professor at a small university, Peter Lyons has developed ways of reaching his research goals with limited funding, and he shares some of them here.